Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC boosted its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 4,965.8% in the first quarter, Holdings Channel reports. The fund owned 27,710 shares of the biotechnology company’s stock after buying an additional 27,163 shares during the quarter. GAMMA Investing LLC’s holdings in Arrowhead Pharmaceuticals were worth $3,530,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $651,000. BNP Paribas Financial Markets increased its stake in Arrowhead Pharmaceuticals by 59.5% during the 4th quarter. BNP Paribas Financial Markets now owns 88,029 shares of the biotechnology company’s stock worth $1,655,000 after buying an additional 32,841 shares during the period. Empowered Funds LLC acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter worth $268,000. Slate Path Capital LP lifted its holdings in Arrowhead Pharmaceuticals by 7.1% in the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company’s stock worth $98,362,000 after buying an additional 347,000 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at about $434,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analysts Set New Price Targets

ARWR has been the topic of a number of analyst reports. Citigroup dropped their target price on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. B. Riley restated a “buy” rating and set a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. Finally, Chardan Capital reissued a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.71.

Insider Activity at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 40,322 shares of Arrowhead Pharmaceuticals stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $10.07, for a total transaction of $406,042.54. Following the sale, the chief executive officer now directly owns 4,022,055 shares in the company, valued at $40,502,093.85. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $16.74 on Thursday. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company’s 50-day moving average price is $14.02 and its 200 day moving average price is $17.31. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $30.41. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of -3.24 and a beta of 0.96.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same quarter in the prior year, the firm earned ($1.02) EPS. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.